Experience with the estrogen receptor antagonist fulvestrant (Faslodex) shows clinical benefit among heavily pretreated postmenopausal women, and when used as first-line therapy for them, it does not preclude further use of endocrine therapy.
Go to Previous Page
Go to Next Page